lawsuit compounded semaglutide can hims still sell Novo Nordisk filed a against telehealth company Hims & FDA sued over 'reckless and

GLP-1 activates the GLP-1 receptor (GLP-1R) in a glucose-dependent manner to potentiate insulin release and suppress glucagon secretion, and thereby lead to blood sugar lowering and weight loss [3][4]

Walking supports cardiovascular health and daily movement, but it does not provide the same muscle-preserving stimulus as progressive resistance training

This rapid appetite suppression happens because semaglutide directly mimics glucagon-like peptide-1, a natural hormone that regulates hunger signals

Switching between semaglutide and tirzepatide is increasingly common, especially for researchers who have plateaued on one compound and want to explore whether a dual agonist (GLP-1/GIP) provides additional benefits

For patients with type 2 diabetes , semaglutide provides significant glycaemic benefits